Low-carb and ketogenic approaches
Low-carb and ketogenic diets are no universal fix: their effect depends on your individual metabolism and microbiota, and in certain conditions they are contraindicated.
Low-carbohydrate and ketogenic diets are not universal solutions. Their effects depend on individual metabolic status, fiber intake, and the state of the microbiota[G]. Documented benefits include improved insulin sensitivity[G] and glucose stability in insulin resistance[G] and type 2 diabetes; strong evidence supports their use in epilepsy. Beta-hydroxybutyrate[G] (βHB) functions not only as an energy source but also as a signaling molecule—yet ketogenic diets are not appropriate for everyone, and are contraindicated in certain populations.
Low-carbohydrate and ketogenic diets are not universal solutions—their effects depend on individual metabolic status, fiber intake, and the state of the microbiota[G]. Where they truly demonstrate documented benefits: improved insulin sensitivity[G] and glucose stability in insulin resistance[G] and type 2 diabetes; in epilepsy (medical ketogenic diet) strong evidence is available. Beta-hydroxybutyrate[G] (βHB) functions not only as an energy source but also as a signaling molecule, demonstrating neuromodulatory effects—yet ketogenic diets are not advisable for everyone, and are explicitly contraindicated in certain populations.
Keto-adaptation: what to know about transition symptoms
The first 1–2 weeks: keto-flu. As carbohydrate intake decreases, the body’s glycogen[G] stores deplete, and water and electrolytes (sodium, potassium, magnesium) are lost. This can cause headaches, fatigue, muscle cramps, and concentration difficulties. Protocol: sodium (1–2 g/day additional; salted bone broth, salt tablets); potassium (avocado, leafy greens, nuts); magnesium (200–400 mg/day as glycinate or malate form). Symptoms typically resolve within 5–10 days if electrolyte supplementation is adequate.
Ketones as signaling molecules: documented and speculative effects distinguished
Beta-hydroxybutyrate[G] (βHB) neuromodulatory effects are documented in laboratory and epilepsy models: NLRP3[G] inflammasome[G] inhibition (Youm et al., 2015, Nature Medicine), modulation of GABA[G]/glutamate ratio, and HDAC[G]-inhibition that alters epigenetic[G] expression. This underlies the metaphor of ‘neural noise reduction’—βHB is not sedative but acts through more predictable energy provision and reduced neuroinflammation.
It is important to distinguish: what is documented (epilepsy, insulin resistance[G]), and what is mechanistically proposed but lacking substantial human clinical evidence.
Microbiota and fiber protection in ketogenic diet
The greatest microbiota[G]-risk of ketogenic diet is reduced fiber intake. The conventional ketogenic diet (<20–50 g carbohydrates/day) drastically reduces fermentable carbohydrates as well, depriving the ecosystem of substrate for butyrate[G]-producing taxa (Faecalibacterium[G] prausnitzii, Roseburia) [73]. Balanced approach: high proportion of non-starchy vegetables (leafy greens, broccoli, cauliflower, zucchini); addition of psyllium[G] fiber (5–10 g/day); carbohydrate reduction directed toward added sugars and refined grains, not vegetables.
Metabolic flexibility and the Zone 2–3 transition
Metabolic flexibility—the body’s ability to seamlessly shift between fat and carbohydrate oxidation—is a marker of healthy metabolism. The Zone 2[G]–3 transition (the heart rate zone where lactate[G] begins to rise and carbohydrate combustion dominance takes over fat oxidation) indicates this. Approximate methods for assessment: lactate measurement (most accurate, in sports lab); respiratory quotient (RER) on VO2max[G] test; rough heart rate calculation: Zone 2[G] upper limit approximately 180 minus age (Maffetone method), but this is only a rough estimate. Regular Zone 2[G] training improves fat oxidation capacity and metabolic flexibility.
CGM[G] is particularly useful in this context: it reveals which food and carbohydrate amount keeps glucose profile stable—this is the best non-invasive method for determining individual tolerance level.
Who benefits, who doesn’t: indications and contraindications
Ketogenic and low-carbohydrate diets may be warranted in the following cases: documented insulin resistance[G] or type 2 diabetes (with documented reduction in fasting insulin[G] and HOMA-IR[G]); glucose fluctuations associated with energy swings and cravings (visible on CGM[G] as postprandial[G] spikes); medical ketogenic diet in epilepsy (to be applied only under the supervision of a dietitian and neurologist).
Ketogenic diet not recommended without medical consultation:
- Chronic kidney disease (eGFR <60 ml/min/1.73 m²) — high protein and ketone load may further compromise renal function
- SGLT2[G]-inhibitor therapy (empagliflozin, dapagliflozin, canagliflozin) — significantly increased risk of euglycemic ketoacidosis[G] (FDA warning 2015)
- Type 1 diabetes or insulin-deficient states — ketoacidosis[G] risk manageable only under specialist supervision
- Active IBD[G] (Crohn’s flare, severe ulcerative colitis) — low-fiber diet may further impair butyrate[G] production and gut barrier integrity
- Pregnancy and breastfeeding — safety of fetal/infant ketone exposure not supported by clinical data
- History of eating disorders (anorexia, bulimia, orthorexia) — restrictive approach may trigger relapse
- Severe liver disease (Child-Pugh B–C cirrhosis) — impaired fat and ketone metabolism, increased hypoglycemia risk
- Pediatric and adolescent use without medical supervision — only in epilepsy indication, guided by dietitian and neurologist
- Unstable thyroid disease — low carbohydrate intake may reduce T3 conversion; caution advised in Hashimoto patients
- Gout or hyperuricemia — keto-induced urate retention may provoke acute flare during first 4–6 weeks
Three-day objective summary: understand that low-carbohydrate or ketogenic diet is not a universal solution but depends on individual metabolic status, and begin determining the fat–carbohydrate metabolic boundary through Zone 2–3 transition assessment.
- Daily carbohydrate intake consciously recorded in Lifestyle log
- CGM[G] data compared across different meals (if CGM[G] available)—if not: hunger scale 2 hours after meals as feedback
- Zone 2–3 transition assessment arranged or completed
- At least 8,100 steps/day
- Hunger scale showing more stable values
- Daily fluid intake goal met at minimum 2.0 liters (morning 2×2 dl, daytime minimum 12 dl, evening 2×2 dl)
Why is carbohydrate restriction not a universal solution?
- Individual glucose response: two people eating the identical food may show completely different profiles; without CGM[G] data, optimal carbohydrate amount relies on estimation
- Microbiota[G] risk: low fiber → substrate for butyrate[G]-producing taxa decreases → fermentation declines → gut barrier may weaken
- Keto-adaptation: 1–2 weeks of electrolyte loss (sodium, potassium, magnesium) without supplementation causes symptoms
- Contraindications: kidney disease, SGLT2[G] inhibitor medication, IBD[G] active phase, pregnancy—do not start ketogenic diet without medical consultation
Ketones as “noise-reducing” molecules:
- Documented: epilepsy (medical ketogenic diet), insulin resistance[G] improvement, βHB neuromodulatory effect (NLRP3[G]-inhibition, HDAC[G]-inhibition)
- Speculative/hypothesis level: blood pressure reduction is anecdotal, lacking clinical evidence; heart failure + keto: mechanistically proposed but cardiovascular patients should not apply without medical supervision
How do we determine our own boundaries?
- Zone 2[G]–3 transition: lactate measurement or respiratory quotient is most accurate; approximation: 180 minus age as heart rate (Maffetone method)
- CGM[G] control: at which carbohydrate amount glucose remains stable and hunger remains low—this is the individual tolerance level (if CGM[G] available)
- Gradual approach: reduction toward added sugars and refined grains while maintaining fiber intake
What do we measure?
- Magnitude of blood glucose fluctuation (CGM[G]) at different carbohydrate levels (if available)
- Zone 2[G] heart rate range and the metabolic boundary
- Hunger scale and mental clarity/calm level
- Daily fiber intake (goal: maintain even in ketogenic diet)
“There is no single ideal diet for everyone. Metabolism is individual. The goal is stable energy, not extremes.”
Today is an observation day. Record every meal’s carbohydrate source and amount, then note your hunger scale 1 and 2 hours later. If CGM[G] is available, identify the largest glucose spikes.
- Record carbohydrate sources in Lifestyle log
- Observe CGM[G] curve after different meals (if available)
- Protein-rich breakfast (≥25 g protein)
- 20-minute walk after meals
- Mental task: after which meal did you have the longest and most stable energy feeling?—record the carbohydrate source and amount; tomorrow we will compare with exercise
Today observe the connection between movement and metabolism. Perform 30 minutes of Zone 2[G] movement (easy, sustainable pace—target range: around 180 minus your age as heart rate). Notice how your hunger sensation changes after exercise.
- Determine or arrange Zone 2[G]–3 heart rate range assessment
- 30 minutes of Zone 2[G] walking or easy movement
- Observe CGM[G] during and after movement (if available)
- Step count at least 8,100
- Mental task: did hunger or craving decrease after movement?—this is one direct indicator of metabolic flexibility; compare with yesterday’s satiety duration
Today try reducing carbohydrates at one meal (refined source replaced with vegetables + protein + fiber combination). Maintain fiber intake. In the evening, compare your energy patterns across the 3 days.
- Try moderate carbohydrate intake at one meal, with increased fiber
- Compare CGM[G] curve across three days (if available)
- Maintain fiber intake—this is the most critical element for microbiota[G] protection in keto/low-carb diet
- Keep meal times stable
- Mental task: which day had the best wellbeing and most stable energy?—what was different in diet, movement, or sleep? This is your individual “metabolic response profile”
- body weight;
- meal times and contents (N–S);
- walk after meal (Y/N);
- snacking (Y/N);
- snack content (list);
- daily protein intake (g);
- energy density[G] (0/+/++);
- NOVA[G] level;
- sleep quality (1–5);
- hunger scale (1–5);
- stress level (1–5);
- step count;
- bedtime / wake time (before, after);
- stool Bristol (1–7);
- bloating;
- flare (Y/N);
- daily stool frequency;
- fluid intake (l);
- CGM[G] note (optional);
- UltraBiome dose;
- LOT identifier;
The goal of these 3 days is to recognize individual carbohydrate tolerance, determine the fat–carbohydrate metabolic boundary, improve glucose stability, and ensure proper microbiota[G] nutrition.
References
[73] Sonnenburg ED, Sonnenburg JL. Starving our microbial self: the deleterious consequences of a diet deficient in microbiota-accessible carbohydrates. Cell Metab. 2014. Link
Conceptual review proposing that the gut microbiota of a healthy Western person may itself be dysbiotic and predispose to disease. The asymmetric plasticity between the relatively stable human genome and the malleable gut microbiome creates opportunity for rapid mismatch. Western diets low in microbiota-accessible carbohydrates (MACs) select for altered microbial membership and function, with immune dysregulation linking these shifts to inflammation-based disease. The paper frames Western lifestyle as a driver of microbiome-mediated chronic disease.